Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
The mean age of participants was 44.05 years (ranging from 32.5 to 58.6 years), with approximately 30.47% being male (34.95% in the GLP-1RAs group and 36.87% in the placebo group)
Angioni D, Middleton L, Bateman R et al (2025) Challenges and opportunities for novel combination therapies in Alzheimers disease: a report from the EU/US CTAD Task Force
Berlin: Agency for Scientific Publ
Recommended Starting Dose of Retatrutide Phase 2 trial protocols typically initiated retatrutide at 2 mg once weekly via subcutaneous injection, allowing gradual physiological adaptation before dose escalation
US$ 25.34
US$ 21.55
US$ 26.14
